Hinge Health price target raised to $66 from $63 at Stifel

Stifel analyst David Grossman raised the firm’s price target on Hinge Health (HNGE) to $66 from $63 and keeps a Buy rating on the shares. The firm’s work – including investor meetings with Hinge management at the firm’s Tech Summit and a proprietary benefit manager survey – suggests there is “significant momentum” behind Hinge’s business, the analyst tells investors.